175 related articles for article (PubMed ID: 35752000)
1. Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images.
Wang CW; Chang CC; Lee YC; Lin YJ; Lo SC; Hsu PC; Liou YA; Wang CH; Chao TK
Comput Med Imaging Graph; 2022 Jul; 99():102093. PubMed ID: 35752000
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract][Full Text] [Related]
3. Interpretable attention-based deep learning ensemble for personalized ovarian cancer treatment without manual annotations.
Wang CW; Lee YC; Lin YJ; Chang CC; Sai AK; Wang CH; Chao TK
Comput Med Imaging Graph; 2023 Jul; 107():102233. PubMed ID: 37075618
[TBL] [Abstract][Full Text] [Related]
4. Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer.
Wang CW; Chang CC; Khalil MA; Lin YJ; Liou YA; Hsu PC; Lee YC; Wang CH; Chao TK
Sci Data; 2022 Jan; 9(1):25. PubMed ID: 35087101
[TBL] [Abstract][Full Text] [Related]
5. A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker.
Wang CW; Lee YC; Chang CC; Lin YJ; Liou YA; Hsu PC; Chang CC; Sai AK; Wang CH; Chao TK
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406422
[TBL] [Abstract][Full Text] [Related]
6. Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer.
Nero C; Boldrini L; Lenkowicz J; Giudice MT; Piermattei A; Inzani F; Pasciuto T; Minucci A; Fagotti A; Zannoni G; Valentini V; Scambia G
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232628
[TBL] [Abstract][Full Text] [Related]
7. Weakly Supervised Deep Learning for Whole Slide Lung Cancer Image Analysis.
Wang X; Chen H; Gan C; Lin H; Dou Q; Tsougenis E; Huang Q; Cai M; Heng PA
IEEE Trans Cybern; 2020 Sep; 50(9):3950-3962. PubMed ID: 31484154
[TBL] [Abstract][Full Text] [Related]
8. The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects.
Mao CL; Seow KM; Chen KH
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805914
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and its use in epithelial ovarian cancer.
Matulonis UA
Future Oncol; 2011 Mar; 7(3):365-79. PubMed ID: 21323425
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in recurrent ovarian cancer.
Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
[TBL] [Abstract][Full Text] [Related]
14. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
16. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
19. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
20. Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study.
Yang Z; Zhang Y; Zhuo L; Sun K; Meng F; Zhou M; Sun J
Eur J Cancer; 2024 Mar; 199():113532. PubMed ID: 38241820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
